|
Title
|
Published
|
Price
|
|
Prostate Cancer Drug Discoveries: What the Future Holds
By: Espicom Healthcare Intelligence
Prostate cancer is the second leading cause of cancer in the US and the third most common cancer worldwide. More than two million men in the US suffer with prostate cancer. Find out more about
|
more...
Search inside this report
|
11/5/2009
|
$2,460.00
|
|
Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
By: La Merie S.L.
The Competitive Intelligence Report FSH, hCG and LH: Therapeutic Proteins for Assisted Reproductive Technology (ART) as of November 2009 provides a competitor analysis in the development pipeline of novel recombinant, transgenic and oral FSH, hCG
|
more...
Search inside this report
|
11/1/2009
|
$297.00
|
|
Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)
By: La Merie S.L.
The Competitive Intelligence Report Thrombopoiesis Stimulating Agents (TPO, IL-11) as of November 2009 provides information on thrombopoiesis stimulating agents targeting the thrombopoietin, interleukin-11 or other receptors on the market and in development.
The product portfolio
|
more...
Search inside this report
|
11/1/2009
|
$223.00
|
|
Canada's Pharmaceutical Industry - Porter’s Five Forces Strategy Analysis
By: Aruvian's R'search
Pharmaceutical is one of the most intense “Knowledge Driven” industries, which is continually in a state of dynamic transition.Diversities in life forms and diseases pose stiff challenge to the design of specific and targeted solutions.
|
more...
Search inside this report
|
11/1/2009
|
$175.00
|
|
Competitor Analysis: FGF-R Agonists and Antagonists
By: La Merie S.L.
The present Competitive Intelligence Report about FGF-R agonists and antagonists provides a competitor evaluation in the field of fibroblast growth factor receptor (FGF-R) or PDGF targeting molecules for wound healing, cardiac tissue repair, bone formation
|
more...
|
11/1/2009
|
$445.00
|
|
BI for Drug Development: Oracle Introduces Clinical Development Analytics
By: IDC
This IDC Health Insights Perspective highlights the announcement of a dedicated life science business intelligence (BI) solution introduced recently at Oracle OpenWorld 2009 that promises to deliver actionable insights into clinical development processes. Oracle Clinical
|
more...
Search inside this report
|
11/1/2009
|
$1,500.00
|
|
Competitor Analysis: TGF-R Agonists and Antagonists
By: La Merie S.L.
The present Competitive Intelligence Report about TGF-R agonists and antagonists provides a competitor evaluation in the field of transforming growth factor receptor (TGF-R) or TGF targeting molecules for tissue healing or treatment of cancer and
|
more...
|
11/1/2009
|
$297.00
|
|
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
By: BioSeeker Group AB
This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of
|
more...
|
10/29/2009
|
$3,500.00
|
|
CDK Inhibitors Patent Landscape 2009
By: France Innovation Scientifique et Transfer
IP Overview presents a patent landscape analysis of the CDK Inhibitor field.
Alterations in CDK activity have been associated in the development of viral infections, neurodegenerative dis orders such as Alzheimer’s disease and proliferative
|
more...
Search inside this report
|
10/29/2009
|
$1,645.00
|
|
Antidiabetics in Australia Market Forecast
By: Datamonitor
Introduction Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest
|
more...
|
10/20/2009
|
$5,700.00
|
|
Plunkett's Health Care Technologies Overview 2010 (Summary)
By: Plunkett Research, Ltd.
This summary contains the complete technologies section excerpted from the highly-acclaimed Plunkett's Health Care Industry Almanac. This report will be your ready-reference guide to new and developing health care technologies. Technology topics range from stem
|
more...
Search inside this report
|
10/16/2009
|
$199.99
|
|
Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases
By: Decision Resources
Introduction
Biomarkers and imaging tools are enabling technologies in today’s clinical research efforts for neurological
diseases. Whether to improve upon existing methods for monitoring disease progression or to discover validated
measures to detect diseases earlier
|
more...
|
10/13/2009
|
$2,250.00
|
|
Patent Foramen Ovale Closure Market: Clinical Trial Outcomes to Play a Key Role
By: GlobalData
Summary Over the last decade there has been considerable evidence gathered, relating Patent Foramen Ovales (PFO) to migraines, cryptogenic stroke and decompression sickeness. There is an increased frequency of PFO in patients suffering from migraine- a
|
more...
|
10/12/2009
|
$500.00
|
|
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
By: Datamonitor
Introduction Drugs with new mechanisms, in particular Pfizer’s oral JAK inhibitor CP-690,550 and Chugai/Roche’s Actemra (tocilizumab), will launch for rheumatoid arthritis and should offer advantages over current therapies, but do not come without some safety signals.
|
more...
|
10/12/2009
|
$11,400.00
|
|
Commercial Insight: Antidepressants - Novel mechanism offers hope in depressed market
By: Datamonitor
Introduction With current blockbuster brands facing generic competition, Datamonitor forecasts the antidepressant market to decline at a compound annual growth rate of -2.0% (20082018). However, an antidepressant with a novel mechanism of action has huge commercial
|
more...
|
10/8/2009
|
$15,200.00
|
|
Commercial Insight: Parkinson's Disease - Japan and Europe to drive total market growth
By: Datamonitor
Introduction The Parkinson's disease market is approaching maturity, with the threat of generic incursion evident in each drug class. Although growth will be stifled by generic launches, relatively successful lifecycle management strategies and new product launches
|
more...
|
10/8/2009
|
$15,200.00
|
|
Parkinson's Disease Market Forecast
By: Datamonitor
Introduction The Parkinson's disease market is approaching maturity, with the threat of generic incursion evident in each drug class. Although growth will be stifled by generic launches, relatively successful lifecycle management strategies and new product launches
|
more...
|
10/2/2009
|
$15,200.00
|
|
Pipeline Insight: HIV - The Age of Convenience
By: Datamonitor
Introduction Three new partnerships are reshaping the competitive environment in HIV. Most notably, Tibotec/Johnson & Johnson is linking up with Gilead to combine their Phase III drug rilpivirine with Truvada to create a new gold standard
|
more...
|
10/2/2009
|
$11,400.00
|
|
Orphan Drug Strategies
By: Datamonitor
Introduction With the pharmaceutical industry reducing its focus on the primary care blockbuster model, Big Pharma is now looking towards the development and commercialization of more niche, high value, often biologic therapies, for the treatment of
|
more...
|
10/2/2009
|
$3,800.00
|
|
Infectious Diseases Drugs Markets
By: Trimark Publications
According to the World Health Organization (WHO), six infectious diseases--pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS--account for half of all premature deaths worldwide, killing mostly children and young adults. What’s more, threatening pandemics such
|
more...
|
10/1/2009
|
$3,400.00
|
|
Contract Pharmaceutical Manufacturing, Research and Packaging
By: BCC Research
REPORT HIGHLIGHTS
Overall sales in the pharmaceutical contract manufacturing and contract research market were worth nearly $143 million in 2007, which increased to an estimated $177 million in 2009. By 2014, sales are
|
more...
Search inside this report
|
10/1/2009
|
$4,850.00
|
|
The World Market for Addiction Disorders, 2009 - 2016
By: Spectra Intelligence
The substance dependence field is transforming into a high-growth market opportunity. Supported by the success of Pfizer's recently launched Chantix/Champix, which is on track for blockbuster status in the smoking cessation sector, pharmacotherapies in development
|
more...
Search inside this report
|
10/1/2009
|
$2,345.00
|
|
Competitor Analysis: Coagulation Factors
By: La Merie S.L.
The present Competitive Intelligence Report about Coagulation Factors provides a competitor evaluation in the field of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of
|
more...
|
10/1/2009
|
$2,115.00
|
|
Competitor Analysis: PDGF-R Agonists and Antagonists
By: La Merie S.L.
The present Competitive Intelligence Report about PDGF-R agonists and antagonists provides a competitor evaluation in the field of platelet derived growth factor receptor (PDGF-R) or PDGF targeting molecules for wound healing, bone formation or treatment
|
more...
|
10/1/2009
|
$1,269.00
|
|
China: A New Era of Innovation in Drug Development
By: CenterWatch
In the latest edition from our Clinical Trials Special Report Series, we break down China’s clinical trials landscape and analyze the government investments and reforms that are making the country more attractive for inclusion in
|
more...
|
10/1/2009
|
$295.00
|
|
Title
|
Published
|
Price
|
(0 items)
